GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (FRA:XE7C) » Definitions » Institutional Ownership

Cardiff Oncology (FRA:XE7C) Institutional Ownership : 12.95% (As of Mar. 04, 2025)


View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cardiff Oncology's institutional ownership is 12.95%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cardiff Oncology's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cardiff Oncology's Float Percentage Of Total Shares Outstanding is 98.10%.


Cardiff Oncology Institutional Ownership Historical Data

The historical data trend for Cardiff Oncology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Institutional Ownership Chart

Cardiff Oncology Historical Data

The historical data trend for Cardiff Oncology can be seen below:

2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31
Institutional Ownership 9.30 9.49 14.20 16.37 15.97 16.44 16.42 16.88 13.27 12.95

Cardiff Oncology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Cardiff Oncology Business Description

Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

Cardiff Oncology Headlines

No Headlines